Cabrimiv 600 mg/300 mg Tablet
PDF Leaflet Revision Date: 16 October 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults and adolescents from 12 years.
Dosage (summary)
One tablet once daily for adults and adolescents; not for those under 40 kg.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding due to potential HIV transmission.
Key Drug Interactions
- Avoid with emtricitabine
- Caution with trimethoprim/sulfamethoxazole
Contraindications
- Hypersensitivity to abacavir or lamivudine
- Severe hepatic impairment
- Severe renal impairment
- Children under 12 years
Common side effects
- Hypersensitivity reactions
- Nausea
- Vomiting
- Diarrhoea
- Rash
- Fever
Counselling Points
- Inform about hypersensitivity risks
- Do not restart if hypersensitivity occurs
- Regular monitoring required during treatment
Serious warnings
- Risk of lactic acidosis
- Severe hypersensitivity reactions
- Potential for mitochondrial dysfunction
Important Disclaimer
The Cabrimiv 600 mg/300 mg Tablet professional information leaflet below is the property of Viatris Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
